CN105189476A - 吡唑衍生物 - Google Patents
吡唑衍生物 Download PDFInfo
- Publication number
- CN105189476A CN105189476A CN201480018955.8A CN201480018955A CN105189476A CN 105189476 A CN105189476 A CN 105189476A CN 201480018955 A CN201480018955 A CN 201480018955A CN 105189476 A CN105189476 A CN 105189476A
- Authority
- CN
- China
- Prior art keywords
- base
- pyrazoles
- formic acid
- cyano group
- pyridine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims (21)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013072788 | 2013-03-29 | ||
JP2013-072788 | 2013-03-29 | ||
PCT/JP2014/059912 WO2014157740A1 (ja) | 2013-03-29 | 2014-03-28 | ピラゾール誘導体 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105189476A true CN105189476A (zh) | 2015-12-23 |
CN105189476B CN105189476B (zh) | 2017-07-07 |
Family
ID=51624694
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201480018955.8A Expired - Fee Related CN105189476B (zh) | 2013-03-29 | 2014-03-28 | 吡唑衍生物 |
Country Status (31)
Country | Link |
---|---|
US (1) | US9617240B2 (zh) |
EP (1) | EP2980085B1 (zh) |
JP (1) | JP6091603B2 (zh) |
KR (1) | KR20150138212A (zh) |
CN (1) | CN105189476B (zh) |
AU (1) | AU2014244855B2 (zh) |
BR (1) | BR112015024462A2 (zh) |
CA (1) | CA2904142A1 (zh) |
CY (1) | CY1120672T1 (zh) |
DK (1) | DK2980085T3 (zh) |
ES (1) | ES2666918T3 (zh) |
HK (1) | HK1219099A1 (zh) |
HR (1) | HRP20180644T1 (zh) |
HU (1) | HUE037813T2 (zh) |
IL (1) | IL241772B (zh) |
LT (1) | LT2980085T (zh) |
ME (1) | ME03055B (zh) |
MX (1) | MX363191B (zh) |
MY (1) | MY176149A (zh) |
NO (1) | NO2980085T3 (zh) |
NZ (1) | NZ712680A (zh) |
PH (1) | PH12015502264A1 (zh) |
PL (1) | PL2980085T3 (zh) |
PT (1) | PT2980085T (zh) |
RS (1) | RS57154B1 (zh) |
RU (1) | RU2632884C2 (zh) |
SA (1) | SA515361238B1 (zh) |
SG (1) | SG11201507939XA (zh) |
SI (1) | SI2980085T1 (zh) |
WO (1) | WO2014157740A1 (zh) |
ZA (1) | ZA201507146B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180095594A (ko) | 2015-12-18 | 2018-08-27 | 노파르티스 아게 | 인단 유도체 및 가용성 구아닐레이트 시클라제 활성화제로서의 그의 용도 |
JP6732004B2 (ja) | 2016-02-19 | 2020-07-29 | 国立大学法人鳥取大学 | 認知症治療薬または予防薬 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0048615A1 (en) * | 1980-09-22 | 1982-03-31 | Eli Lilly And Company | Improvements in or relating to 3-aryl-5-isothiazole derivatives |
WO1999055693A2 (en) * | 1998-04-28 | 1999-11-04 | Novartis Ag | N-heteroaryl-substituted pyridine derivatives and their use as herbicides |
WO2005111003A1 (en) * | 2004-04-29 | 2005-11-24 | Abbott Laboratories | Amino-tetrazoles analogues and methods of use |
WO2007113226A1 (en) * | 2006-03-31 | 2007-10-11 | Novartis Ag | Organic compounds |
CN101282934A (zh) * | 2005-10-07 | 2008-10-08 | 安斯泰来制药株式会社 | 三芳基羧酸衍生物 |
CN101282936A (zh) * | 2005-10-07 | 2008-10-08 | 橘生药品工业株式会社 | 氮化杂环化合物及包含其的药物组合物 |
WO2010044403A1 (ja) * | 2008-10-15 | 2010-04-22 | キッセイ薬品工業株式会社 | 5員環ヘテロアリール誘導体及びその医薬用途 |
WO2011011712A1 (en) * | 2009-07-24 | 2011-01-27 | Concert Pharmaceuticals, Inc. | Substituted imidazotriazines |
WO2011019780A1 (en) * | 2009-08-11 | 2011-02-17 | Bristol-Myers Squibb Company | Azaindazoles as btk kinase modulators and use thereof |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4495195A (en) | 1982-11-01 | 1985-01-22 | Eli Lilly And Company | Xanthine oxidase inhibiting 3(5)-phenyl-substituted-5(3)-pyrazole-carboxylic acid derivatives, compositions, and methods of use |
ID21775A (id) | 1996-10-25 | 1999-07-22 | Yoshitomi Pharmaceutical | Senyawa-senyawa 1-fenilpirazol dan penggunaan farmasinya |
JPH10310578A (ja) | 1996-11-13 | 1998-11-24 | Yoshitomi Pharmaceut Ind Ltd | 3−フェニルピラゾール化合物 |
WO1999065885A1 (en) * | 1998-06-19 | 1999-12-23 | Teijin Limited | Polymorphic modifications of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazole-carboxylic acid and processes for the preparation thereof |
JP2007043457A (ja) | 2005-08-03 | 2007-02-15 | Masamichi Mochizuki | 携帯電話 |
JP4849594B2 (ja) | 2005-09-30 | 2012-01-11 | フマキラー株式会社 | 送風式薬剤放散装置 |
US8067446B2 (en) | 2006-02-24 | 2011-11-29 | Astellas Pharma Inc. | Methods for treating an ulcer of the small intestine and stomach |
JP5132132B2 (ja) | 2006-11-17 | 2013-01-30 | ヤマハ発動機株式会社 | 船舶用操舵装置及び船舶 |
JP2008126770A (ja) | 2006-11-17 | 2008-06-05 | Big Tool Co Ltd | 自動車用窓ガラスの取り外し方法 |
WO2008126772A1 (ja) | 2007-04-05 | 2008-10-23 | Astellas Pharma Inc. | 高血圧治療剤 |
WO2008126770A1 (ja) | 2007-04-05 | 2008-10-23 | Astellas Pharma Inc. | トリアリールカルボン酸誘導体の製造方法 |
JP4939578B2 (ja) | 2009-08-19 | 2012-05-30 | 株式会社沖データ | 現像剤搬送装置、現像剤収容器、及び画像形成装置 |
TWI423962B (zh) | 2009-10-07 | 2014-01-21 | Lg Life Sciences Ltd | 有效作為黃嘌呤氧化酶抑制劑之新穎化合物、其製備方法及含該化合物之醫藥組成物 |
-
2014
- 2014-03-28 RS RS20180453A patent/RS57154B1/sr unknown
- 2014-03-28 JP JP2015508836A patent/JP6091603B2/ja not_active Expired - Fee Related
- 2014-03-28 DK DK14775913.8T patent/DK2980085T3/en active
- 2014-03-28 CN CN201480018955.8A patent/CN105189476B/zh not_active Expired - Fee Related
- 2014-03-28 ES ES14775913.8T patent/ES2666918T3/es active Active
- 2014-03-28 EP EP14775913.8A patent/EP2980085B1/en active Active
- 2014-03-28 SI SI201430658T patent/SI2980085T1/en unknown
- 2014-03-28 RU RU2015141274A patent/RU2632884C2/ru active
- 2014-03-28 MX MX2015013333A patent/MX363191B/es unknown
- 2014-03-28 KR KR1020157026553A patent/KR20150138212A/ko active IP Right Grant
- 2014-03-28 ME MEP-2018-105A patent/ME03055B/me unknown
- 2014-03-28 PT PT147759138T patent/PT2980085T/pt unknown
- 2014-03-28 CA CA2904142A patent/CA2904142A1/en not_active Abandoned
- 2014-03-28 HU HUE14775913A patent/HUE037813T2/hu unknown
- 2014-03-28 SG SG11201507939XA patent/SG11201507939XA/en unknown
- 2014-03-28 LT LTEP14775913.8T patent/LT2980085T/lt unknown
- 2014-03-28 NO NO14775913A patent/NO2980085T3/no unknown
- 2014-03-28 PL PL14775913T patent/PL2980085T3/pl unknown
- 2014-03-28 AU AU2014244855A patent/AU2014244855B2/en not_active Ceased
- 2014-03-28 US US14/774,517 patent/US9617240B2/en active Active
- 2014-03-28 BR BR112015024462A patent/BR112015024462A2/pt active Search and Examination
- 2014-03-28 WO PCT/JP2014/059912 patent/WO2014157740A1/ja active Application Filing
- 2014-03-28 MY MYPI2015703292A patent/MY176149A/en unknown
- 2014-03-28 NZ NZ712680A patent/NZ712680A/en not_active IP Right Cessation
-
2015
- 2015-09-21 IL IL241772A patent/IL241772B/en active IP Right Grant
- 2015-09-28 SA SA515361238A patent/SA515361238B1/ar unknown
- 2015-09-28 ZA ZA2015/07146A patent/ZA201507146B/en unknown
- 2015-09-29 PH PH12015502264A patent/PH12015502264A1/en unknown
-
2016
- 2016-06-21 HK HK16107092.4A patent/HK1219099A1/zh not_active IP Right Cessation
-
2018
- 2018-04-24 HR HRP20180644TT patent/HRP20180644T1/hr unknown
- 2018-04-30 CY CY181100450T patent/CY1120672T1/el unknown
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0048615A1 (en) * | 1980-09-22 | 1982-03-31 | Eli Lilly And Company | Improvements in or relating to 3-aryl-5-isothiazole derivatives |
WO1999055693A2 (en) * | 1998-04-28 | 1999-11-04 | Novartis Ag | N-heteroaryl-substituted pyridine derivatives and their use as herbicides |
WO2005111003A1 (en) * | 2004-04-29 | 2005-11-24 | Abbott Laboratories | Amino-tetrazoles analogues and methods of use |
CN101282934A (zh) * | 2005-10-07 | 2008-10-08 | 安斯泰来制药株式会社 | 三芳基羧酸衍生物 |
CN101282936A (zh) * | 2005-10-07 | 2008-10-08 | 橘生药品工业株式会社 | 氮化杂环化合物及包含其的药物组合物 |
WO2007113226A1 (en) * | 2006-03-31 | 2007-10-11 | Novartis Ag | Organic compounds |
WO2010044403A1 (ja) * | 2008-10-15 | 2010-04-22 | キッセイ薬品工業株式会社 | 5員環ヘテロアリール誘導体及びその医薬用途 |
WO2011011712A1 (en) * | 2009-07-24 | 2011-01-27 | Concert Pharmaceuticals, Inc. | Substituted imidazotriazines |
WO2011019780A1 (en) * | 2009-08-11 | 2011-02-17 | Bristol-Myers Squibb Company | Azaindazoles as btk kinase modulators and use thereof |
Non-Patent Citations (2)
Title |
---|
CAILLY THOMAS ET AL.: "Regioselective functionalization of 2-(2’-fluorophenyl)-3-cyanopyridine and its cyclization to benzo[h]-1,6-naphthyridines", 《TETRAHEDRON》 * |
TUTONDA,M. ET AL.: "Diels-Alder reactions of the heterodiene system in 2(1H)-pyrazinones", 《TETRAHEDRON LETTERS》 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5596139B2 (ja) | 二置換フタラジンヘッジホッグ経路アンタゴニスト | |
CN104968662A (zh) | 唑苯衍生物 | |
TW202104189A (zh) | 雙環化合物 | |
EP3059227B1 (en) | Salt of nitrogen-containing heterocyclic compound or crystal thereof, pharmaceutical composition, and flt3 inhibitor | |
WO2018022761A1 (en) | Substituted cyclopentane-amides for treating disorders related to ret | |
BRPI0708507A2 (pt) | Novos antagonistas de receptores de dupla ação (dara) para os receptores at1 eta | |
JP5518887B2 (ja) | 四置換ピリダジンヘッジホッグ経路アンタゴニスト | |
KR101866706B1 (ko) | 1-알킬-6-옥소-1,6-디하이드로피리딘-3-일 화합물과 sgrm 조절인자로서의 용도 | |
CN102015707A (zh) | Raf抑制剂化合物及其使用方法 | |
US20110039895A1 (en) | Prolyl hydroxylase inhibitors | |
CN105001213A (zh) | C-芳基糖苷衍生物、其药物组合物、制备方法及应用 | |
CN112778284A (zh) | 一种嘧啶并环衍生物及其在医药上的应用 | |
CN106660970A (zh) | 喹唑啉衍生物 | |
CN105189476A (zh) | 吡唑衍生物 | |
CA2658285C (en) | Thieno[3,2-c]pyridine-7-carboxylic acid derivatives for use in treating solid tumors | |
CN105017236A (zh) | C-芳基糖苷衍生物、其药物组合物、制备方法及应用 | |
CN109111439B (zh) | 一种酰胺类化合物及包含该化合物的组合物及其用途 | |
CN109336829B (zh) | 含1,2,3-三氮唑结构的芳基甲酰胺类化合物及其用途 | |
WO2023207556A1 (zh) | Prmt5-mta抑制剂 | |
TW202302586A (zh) | 作為甲硫胺酸腺苷轉移酶抑制劑的化合物、其製備方法及應用 | |
JPWO2013081094A1 (ja) | イミダゾ[1,2−a]ピリジン誘導体及びその医薬用途 | |
KR20080015045A (ko) | 헤테로아릴에테닐 유도체, 이의 제조 및 약학 제제로서의용도 | |
WO2014192977A1 (ja) | チアゾール誘導体 | |
CN115260194A (zh) | 新型egfr降解剂 | |
JP2016193887A (ja) | オートタキシン阻害活性を有する縮合9員環誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1219099 Country of ref document: HK |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1219099 Country of ref document: HK |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20181116 Address after: Osaka City, Osaka of Japan Patentee after: TEIJIN Ltd. Address before: Tokyo, Japan Patentee before: Teijin Pharma Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170707 |